GlassScriptPhysician profile
Dorotea Gabel
NPI 1336110410
$3,403.89
in general payments reported to CMS, 2019-2025
36 companies · $503 in 2025
The $503 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,053 · 2020: $530 · 2021: $518 · 2022: $282 · 2023: $312 · 2024: $205 · 2025: $503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,020.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,020.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $490.65 | 2019-2025 | Evenity, Repatha, Otezla |
| Amarin Pharma, INC. | $451.97 | 2019-2021 | |
| Abbvie INC. | $278.58 | 2021-2023 | |
| Astellas Pharma US INC | $240.99 | 2019-2025 | Veozah |
| Pfizer INC. | $234.84 | 2019-2025 | |
| Inari Medical, INC. | $199.20 | 2021-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Astrazeneca Pharmaceuticals LP | $171.33 | 2019-2025 | Airsupra, Breztri |
| Novo Nordisk INC | $140.99 | 2019-2025 | Wegovy |
| Novartis Pharmaceuticals Corporation | $131.12 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $127.40 | 2019-2025 | |
| Glaxosmithkline, LLC. | $114.04 | 2019-2023 | Shingrix |
| Dexcom, INC. | $102.90 | 2023-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.71 | 2019-2022 | |
| Lilly USA, LLC | $58.25 | 2019-2025 | Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $53.97 | 2024-2025 | Rexulti |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $41.79 | 2025 | Intellis Adaptivestim |
| Janssen Pharmaceuticals, INC | $39.74 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $37.63 | 2021-2022 | |
| Eisai INC. | $37.32 | 2019 | |
| Abbott Laboratories | $37.25 | 2021-2023 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $35.77 | 2022 | |
| Exact Sciences Corporation | $30.85 | 2024-2025 | Cologuard Collection Kit |
| Arbor Pharmaceuticals, INC. | $30.83 | 2020 | |
| Merck Sharp & Dohme LLC | $28.11 | 2020 | |
| Edwards Lifesciences Corporation | $24.66 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Esperion Therapeutics, INC. | $23.12 | 2020 | |
| Radius Health, INC. | $21.52 | 2025 | Tymlos |
| E.R. Squibb & Sons, L.L.C. | $19.16 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.00 | 2019 | |
| Phathom Pharmaceuticals, INC. | $18.17 | 2025 | Voquezna |
| Genentech USA, INC. | $15.00 | 2019 | |
| Nabriva Therapeutics, Plc | $13.39 | 2020 | |
| Ibsa Pharma INC. | $13.36 | 2020 | |
| Hikma Pharmaceuticals USA | $13.30 | 2020 | |
| Sanofi Pasteur INC. | $12.00 | 2020 | |
| Paratek Pharmaceuticals, INC. | $11.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dorotea Gabel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.